SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the results of the Phase III SERENA-6 trial - sponsored by AstraZeneca - demonstrate the clinical value of the Guardant360® CDx test in a circulating tumor DNA-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of radiological disease progression in breast cancer. Study results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and were published in The New England Journal of Medicine.
SERENA-6 is the first global, double-blind, registrational Phase III trial to use a ctDNA-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before disease progression is detected in imaging scans. The novel trial design used ctDNA monitoring with the Guardant360 liquid biopsy test at the time of routine tumor scans to identify patients for early signs of endocrine resistance and the emergence of ESR1 mutations.
'SERENA-6 is a landmark study that is creating a new paradigm using liquid biopsy to enable a switch to a new treatment as soon as you see the cancer showing signs of resistance,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'This use of the Guardant360 CDx test highlights how we are pushing the boundaries of what can be done with liquid biopsy in characterizing disease and potential drug efficacy, providing insights that could potentially change clinical practice and improve outcomes in patients with advanced breast cancer.'
Following detection of an ESR1 mutation without radiological disease progression, the endocrine therapy of patients was switched to AstraZeneca's camizestrant from ongoing treatment with an aromatase inhibitor (AI), while continuing combination with the same cyclin-dependent kinase (CDK) 4/6 inhibitor. The trial demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors had an emergent ESR1 mutation as detected by Guardant360 CDx.
About Guardant360 CDx
The first FDA-approved blood test for complete genomic testing, Guardant360 CDx is approved as a companion diagnostic fur multiple therapies in non-small cell lung cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives. For more information, visit the Guardant360 CDx website.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

26 minutes ago

• Business Wire

CEA Opens Shanghai–Auckland–Buenos Aires "New International Land-Sea Trade Corridor" to First Bridge China and South America

SHANGHAI--(BUSINESS WIRE)--On June 18, 2025, China Eastern Airlines (CEA) and Auckland Airport signed a cooperation agreement in Shanghai. According to the plan, CEA will launch commercial flights in December 2025 from Shanghai Pudong International Airport to Ministro Pistarini International Airport via Auckland Airport. The signing ceremony was attended by government officials, corporate representatives, and heads from relevant departments. New Zealand's Prime Minister Christopher Luxon highlighted that the new route will enhance global connectivity by linking Auckland with the dynamic economies of Asia and South America. He also announced that New Zealand will implement a visa-free transit policy for Chinese travelers passing through Auckland. Since the opening of the route to Auckland in 2014, CEA has shown strong growth. Chairman Wang Zhiqing stated that the airline will leverage its Shanghai hub to accelerate the construction of its global route network. The new route will serve as a vital bridge among New Zealand, China, the Asia-Pacific region, and South America, supporting the Belt and Road Initiative. Auckland Airport expressed satisfaction with the imminent realization of the jointly envisioned " New International Land-Sea Trade Corridor". CEA, Auckland Airport's key partner and now the leading carrier on the China–New Zealand route, has maintained steady operations and consistently expanded capacity. The new service, to be operated twice weekly by Boeing 777, will be the only direct air link between Argentina and China, filling the gap in direct air services between the two nations. The "New International Land-Sea Trade Corridor" shortens travel time by 4–5 hours versus European or North American routes and offers direct flights, while also reducing jet lag—passengers only face a 4-hour time difference when transiting through Auckland, as opposed to 12 hours via traditional Western routes. CEA plans to apply for fifth freedom for this route, enabling passenger and cargo transport in Auckland, boosting economic, trade, and people-to-people exchanges among New Zealand, China, and Argentina. Currently, CEA operates flights from Auckland to both Shanghai Pudong and Hangzhou Xiaoshan. Following the new route launch, CEA will boost New Zealand–China capacity deployment, increasing Auckland–Shanghai flights from 7 to 9 weekly. Note: The new route remains subject to final regulatory approval.

Time Business News

2 hours ago

• Time Business News

Your Guide to Botox and Lip Fillers in El Segundo

If you've ever looked in the mirror and thought, 'Hmm, maybe just a little boost,' you're not alone. Botox and lip fillers have become incredibly popular, especially among people who want a natural, refreshed look without surgery. In El Segundo, more and more locals are discovering the power of subtle cosmetic treatments. Whether it's smoothing out a few lines or adding volume to your lips, the right provider can make all the difference. That's why so many people are turning to this clinic, known for its careful work and personalized results. Let's clear up the myths first. Botox isn't about 'freezing your face.' It's a simple treatment that relaxes the muscles under your skin, mostly in areas where fine lines form from repeated facial expressions like frowning or smiling. It's FDA-approved and has been used safely for years. Most people use Botox to reduce lines around the forehead, between the eyebrows, and around the eyes (those 'crow's feet'). Treatments take just 10–15 minutes, and you can go back to your day right after. The results appear within a few days and can last three to four months. It's not permanent, which means you can always adjust how much or how little you want in future visits. Lip fillers are perfect if you want fuller, smoother, or more balanced lips. Most fillers today use hyaluronic acid—a substance your body already makes. It adds volume and shape in a way that feels soft and natural. You don't need to go for an over-the-top look. In fact, many people use fillers to correct asymmetry or just add a touch of definition. The procedure usually takes under 30 minutes, and results are immediate. Swelling may happen for a day or two, but it's usually mild. With proper care, lip fillers can last from 6 months to a full year. Most adults are good candidates, but your provider will always check your medical history to make sure it's safe for you. These treatments are great for: ● People see early signs of aging ● Anyone wanting subtle improvements ● Those preparing for events like weddings or reunions ● People who want to boost their confidence What's important is going to a qualified injector. You don't want just anyone putting a needle in your face. A licensed expert knows how to enhance your natural features, not change them. If it's your first time, don't worry. Most clinics make the process easy and comfortable. Here's how it usually works: 1. Consultation: You'll talk about what you want, ask questions, and get expert advice. 2. Prep: The provider may mark the treatment areas and apply a numbing cream if needed. 3. Injection: It takes just minutes to do the actual injections. 4. Aftercare: You'll get tips on how to avoid swelling or bruising, like skipping alcohol or heavy workouts for a day. You may be surprised by how quick and simple the whole thing is. Myth 1: Botox and fillers are only for older people. Truth: Many younger people use these treatments to prevent lines before they form. Myth 2: You'll look fake or 'done.' Truth: When done right, the results look natural and fresh—not frozen or overfilled. Myth 3: It's super painful. Truth: Most people say it feels like a tiny pinch or quick sting. Plus, numbing options help. Don't just look at price—look at experience and reputation. Read reviews. Check before-and-after photos. Ask how many years they've been doing this work. A great provider listens, explains clearly, and never pressures you into getting more than you need. Also, make sure the place is clean, licensed, and uses approved products. You deserve the best care for your face. Getting Botox or lip fillers or any form of cosmetic help isn't about changing who you are. It's about feeling confident in your skin and doing something for you . Whether you're after smoother skin or fuller lips, a little enhancement can go a long way when done right. Ready to explore your options in El Segundo? A good first step is booking a consultation and asking questions. You'll be amazed at how small changes can lead to a big boost in self-esteem. TIME BUSINESS NEWS

Yahoo

3 hours ago

• Yahoo

AeroVironment (AVAV) Reports Earnings Tomorrow: What To Expect

Aerospace and defense company AeroVironment (NASDAQ:AVAV) will be announcing earnings results this Tuesday afternoon. Here's what investors should know. AeroVironment missed analysts' revenue expectations by 10.9% last quarter, reporting revenues of $167.6 million, down 10.2% year on year. It was a disappointing quarter for the company, with full-year revenue guidance missing analysts' expectations significantly and full-year EBITDA guidance missing analysts' expectations significantly. Is AeroVironment a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting AeroVironment's revenue to grow 23.7% year on year to $243.7 million, improving from the 5.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.41 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. AeroVironment has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 5.6% on average. Looking at AeroVironment's peers in the aerospace and defense segment, some have already reported their Q1 results, giving us a hint as to what we can expect. HEICO delivered year-on-year revenue growth of 14.9%, beating analysts' expectations by 3.5%, and Redwire reported a revenue decline of 30.1%, falling short of estimates by 16.5%. HEICO traded up 7.4% following the results while Redwire's stock price was unchanged. Read our full analysis of HEICO's results here and Redwire's results here. Investors in the aerospace and defense segment have had steady hands going into earnings, with share prices flat over the last month. AeroVironment is up 7.2% during the same time and is heading into earnings with an average analyst price target of $195.38 (compared to the current share price of $190.94). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.